The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update

Merhi, Maysaloun; Faried, Ahmad; Taib, Nassiba; Inchakalody, Varghese; Uddin, Shahab; Shablak, Alaaeldin; Dermime, Said

doi:10.1016/j.semcancer.2023.01.001

Cited by 12 publications

(5 citation statements)

References 328 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CRC, the expression of JUN was reported to be upregulated and play an important role in the cancer progression by making a complex with the TCF4 and βcatenin (CTNNB1) transcription factors. 73,74 CTNNB1 was also identified as a key dysregulated gene in our analysis. It is a part of the Wnt signaling pathway, which regulates various biochemical processes such as cancer Cell Proliferation, metabolism, inflammation and immunization, heterogeneity and metastasis.…”

Section: Discussionmentioning

confidence: 76%

“…JUN, also known as C‐Jun, is a part of the AP‐1 transcription factor family and common TFs among different pathways, including the immune‐related pathway, focal adhesion, MAPK, and Wnt signaling pathways. In CRC, the expression of JUN was reported to be upregulated and play an important role in the cancer progression by making a complex with the TCF4 and β‐catenin (CTNNB1) transcription factors 73,74 . CTNNB1 was also identified as a key dysregulated gene in our analysis.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Integrative network analysis of transcriptomics data reveals potential prognostic biomarkers for colorectal cancer

Mahajan,

Sarkar,

Mondal

2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionCross‐talk among biological pathways is essential for normal biological function and plays a significant role in cancer progression. Through integrated network analysis, this study explores the significance of pathway cross‐talk in colorectal cancer (CRC) development at both the pathway and gene levels.MethodsIn this study, we integrated the gene expression data with domain knowledge to construct state‐dependent pathway cross‐talk networks. The significance of the genes involved in pathway cross‐talk was assessed by analyzing their association with cancer hallmarks, disease‐gene relation, genetic alterations, and survival analysis. We also analyzed the gene regulatory network to identify the dysregulated genes and their role in CRC progression.ResultsCross‐talk was observed between immune‐related pathways and pathways associated with cell communication and signaling. The PTPRC gene was identified as a mediator, facilitating interactions within the immune system and other signaling pathways. The rewired interactions of ITGA7 were identified as influential in the epithelial‐mesenchymal transition in CRC. This study also highlighted the crucial link between cell communication and vascular smooth muscle contraction pathway in CRC progression. The survival analysis of identified gene clusters showed their significant prognostic value in distinguishing high‐risk from low‐risk CRC groups, and L1000CDS2 revealed seven potential drug molecules in CRC. Nine dysregulated genes (CTNNB1, EP300, JUN, MYC, NFKB1, RELA, SP1, STAT1, and TP53) emerge as transcription factors acting as common regulators across various pathways.ConclusionsThis study highlights the crucial role of pathway cross‐talk in CRC progression and identified the potential prognostic biomarkers and potential drug molecules.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 77%

Integrative network analysis of transcriptomics data reveals potential prognostic biomarkers for colorectal cancer

Mahajan,

Sarkar,

Mondal

2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In general, transcription factors are responsible for modulating downstream target genes through transcriptional regulation [ 23 ]. ZNF274 has mainly been discussed in the context of neurobehavioral disorders [ 11 , 13 , [24] , [25] , [26] ].…”

Section: Discussionmentioning

confidence: 99%

IL-8-mediated overexpression of ZNF274 promotes the proliferation and migration of colorectal cancer cells through the transactivation of MRPL40

Zhang

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Aflibercept can be used as a second-line treatment for mCRC that has progressed or is resistant to an oxaliplatin-containing regimen in combination with FOLFIRI. It has been linked to manageability and a dramatically increased PFS [36]. Aflibercept, an inhibitor of vascular endothelial growth factor, most commonly results in hypertension; less frequently, HF, ATEs, and VTEs occur.…”

Section: Novel Agentsmentioning

confidence: 99%

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

Kashyap,

Mangrulkar,

Kushwaha

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF/Ras/Raf/MEK/ERK, and the PI3/ERK/AMPK/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy.

show abstract

The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update

Cited by 12 publications

References 328 publications

Integrative network analysis of transcriptomics data reveals potential prognostic biomarkers for colorectal cancer

Integrative network analysis of transcriptomics data reveals potential prognostic biomarkers for colorectal cancer

IL-8-mediated overexpression of ZNF274 promotes the proliferation and migration of colorectal cancer cells through the transactivation of MRPL40

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

Contact Info

Product

Resources

About